61578-04-9

Basic information

• Product Name: [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran
• Synonyms: [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran;[[4-(alpha,alpha-dimethylbenzyl)phenoxy]methyl]oxirane;PARA-CUMYLPHENYLGLYCIDYLETHER;[[4-(1-Methyl-1-phenylethyl)phenoxy]methyl]oxirane;2-[[4-(2-phenylpropan-2-yl)phenoxy]methyl]oxirane;Cumylphenyl glycidyl ether, p-;EINECS 262-857-9;Oxirane, ((4-(1-methyl-1-phenylethyl)phenoxy)methyl)-
• CAS NO: 61578-04-9
• Molecular Formula: C₁₈H₂₀O₂
• Molecular Weight: 268.3502
• EINECS: 262-857-9
• Mol File: 61578-04-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran(CAS DataBase Reference)
• NIST Chemistry Reference: [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran(61578-04-9)
• EPA Substance Registry System: [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran(61578-04-9)

Safety Data

• Hazardous Substances Data: 61578-04-9(Hazardous Substances Data)

Usage

Reactivity Profile

[[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran is an ether. Ethers may react violently with strong oxidizing agents. In other reactions, which typically involve the breaking of the carbon-oxygen bond, ethers are relatively inert.

Fire Hazard

Flash point data for [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran are not available. [[4-(1-methyl-1-phenylethyl)phenoxy]methyl]-oxiran is probably combustible.

Relevant articles and documents

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.